Advance Malignancies
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Safety, Tolerability & PK of KX2-361 in Subjects w Adv. Malignancies Refractory to Conventional Therapies (NCT02326441) | Athenex, Inc. | 2014-12-01 |
Track Advance Malignancies automatically
Every clearance here is in the API, with alerts when new ones post.